Financial comparisons Monte Rosa Therapeutics, Inc.
Stocks
GLUE
US61225M1027
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
01:30:00 03/10/2026 am IST
|
5-day change | 1st Jan Change | ||
| 10.50 USD | -6.75% |
|
-10.79% | -33.04% |
| 01/10 | Monte Rosa Therapeutics Announces Positive Data From GFORCE-1 Phase 1 Study Evaluating MRT-8102 | CI |
| 01/10 | Monte Rosa Therapeutics, Inc. - Special Call |
Main competitors
| Revenues (Y-1) | Net Margin (Y-1) | EBIT Margin (Y-1) | ROE (Y-1) | ROA (Y-1) | Leverage (Y-1) | ||
|---|---|---|---|---|---|---|---|
 | 12Cr | -31.23% | -43.83% | -16.94% | -8.71% | - | |
| 649.89Cr | 42.13% | 52.64% | 28.56% | 20.88% | -0.99x | |
| 424.8Cr | 30.41% | 24.81% | 20.15% | 17.36% | -3.18x | |
| 823.63Cr | 14.53% | 21.7% | 10.28% | 4.9% | 1.58x | |
| 1.63TCr | 8.34% | 13.38% | 32.9% | 4.79% | 3.63x | |
| 534.3Cr | 5.37% | 8.37% | 29.84% | 16.27% | -5.99x | |
| 288.36Cr | 24.74% | 28.07% | 5.94% | 4.75% | 1.77x | |
| 311.53Cr | 22.53% | 31.44% | 11.9% | 8.13% | -1.19x | |
| 336.96Cr | -39.59% | -48.95% | -5.88% | -5.1% | 6.99x | |
| 61Cr | -210.54% | -205.59% | -249.28% | - | 0.72x | |
| 369.4Cr | 25.89% | 28.63% | 17.53% | 9.99% | -1.51x | |
| 253.02Cr | 17.83% | 20.93% | 70.23% | 22.13% | -0.89x | |
| 50Cr | 32.27% | 31.52% | 16.97% | 14.74% | -3.83x | |
| 85Cr | -31.67% | -18.92% | - | - | 1.57x | |
| 856.64Cr | 6.51% | 14.79% | 9.61% | 4.34% | 2.22x | |
| 232.01Cr | 33.73% | 37.59% | 35.53% | 27.02% | -1.18x | |
| 29Cr | -18.56% | -24.05% | -9.34% | -9.05% | 8.22x | |
| 401.54Cr | -3.59% | 19.77% | 15.46% | 6.99% | 1.98x | |
| 127.18Cr | -19.27% | -3.71% | -38.64% | -6.61% | -65.61x | |
| Average | 393.53Cr | -4.75% | -0.6% | -0.84% | 7.81% | -3.09x | |
| Weighted average by Cap. | 525.32Cr | 4.48% | 8.99% | 5.42% | 10.66% | -1.75x |
- Stock Market
- Stocks
- GLUE Stock
- Sector Monte Rosa Therapeutics, Inc.
- Financial comparisons
Select your edition
All financial news and data tailored to specific country editions
